ORLANDO, FLA.—Current genetic testing guidelines, which were established nearly 20 years ago, exclude many patients who harbor high-risk mutations and would benefit from such testing, according to two studies comparing populations of people who did and did not meet guideline criteria for genetic testing.
One study found that breast cancer patients had a similar number of pathogenic mutations regardless of whether they met the National Comprehensive Cancer Network (NCCN) genetic testing